Tillmann, Hans L

AbstractBackgroundCompeting causes of liver injury may be difficult to discriminate. Characterization of the typical phenotype of each injury defined by latency, time to improvement and biochemical pattern, could be helpful to identify the most likely of competing causes.MethodsLiver injury characteristics of both bortezomib‐associated drug‐induced liver injury (DILI) and hepatitis B virus (HBV) reactivation associated with bortezomib are derived from PubMed listed publications.ResultsBortezomib‐associated DILI has very short latency of days and AP is found elevated, while liver injury due to HBV reactivation occurs after several months of bortezomib therapy. Therefore, a patient's liver injury pattern occurring 3 months into bortezomib therapy should be attributed to HBV reactivation.DiscussionIdentification of liver injury characteristics for competing causes of liver injury can be helpful to identify the most likely cause and improve clinical outcome.